Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ: IBRX )

3.420 -0.220 (-6.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,166,156
Open 3.660
Bid (Size) 3.400 (11)
Ask (Size) 3.460 (1)
Prev. Close 3.640
Today's Range 3.400 - 3.750
52wk Range 2.280 - 10.53
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment. 
Via Stocktwits
Exposures Product Safety
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
Via Benzinga

Performance

YTD
+33.07%
+33.07%
1 Month
+6.21%
+6.21%
3 Month
-32.94%
-32.94%
6 Month
-19.53%
-19.53%
1 Year
-34.73%
-34.73%

More News

Read More
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
From ImmunityBio, Inc.
Via Business Wire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
Via Stocktwits
Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
Via Benzinga
Exposures Product Safety
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
From ImmunityBio, Inc.
Via Business Wire
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
From D. Boral Capital
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With ImmunityBio Shares Wednesday?
Via Benzinga
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
From ImmunityBio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.